Get the Stockscreener App
16.52
27.16%
-6.16
Monte Rosa Therapeutics Inc stock is traded at $16.52, with a volume of 7.45M.
It is down -27.16% in the last 24 hours and down -31.74% over the past month.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
See More
Previous Close:
$22.68
Open:
$15.47
24h Volume:
7.45M
Relative Volume:
6.62
Market Cap:
$1.40B
Revenue:
$42.95M
Net Income/Loss:
$-130.01M
P/E Ratio:
-10.15
EPS:
-1.6278
Net Cash Flow:
$-19.66M
1W Performance:
-27.48%
1M Performance:
-31.74%
6M Performance:
-19.49%
1Y Performance:
+233.74%
1-Day Range:
$14.87
$16.85
1-Week Range:
$14.87
$23.65
52-Week Range:
$4.12
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
16.52 | 1.91B | 42.95M | -130.01M | -19.66M | -1.6278 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Exome Asset Management LLC Takes $2.95 Million Position in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics Inc (GLUE) Cash Flow - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Income Statement - TradingKey
Monte Rosa Therapeutics, Inc. Revenue Breakdown – BOATS:GLUE - TradingView
Monte Rosa Therapeutics Inc (GLUE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GLUE|Monte Rosa Therapeutics Inc|Price:22.570|Chg%:-0.210 - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Monte Rosa Therapeutics Inc (GLUE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
GLUE|Monte Rosa Therapeutics Inc|Price:22.780|Chg%:-0.250 - TradingKey
Price to sales forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Monte Rosa Therapeutics Market Sentiment - Benzinga España
Price to sales forward of Monte Rosa Therapeutics, Inc. – BOATS:GLUE - TradingView
Allspring Global Investments Holdings LLC Buys 365,272 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight - The Manila Times
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight - GlobeNewswire Inc.
Enterprise value to EBITDA forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Have Insiders Sold Monte Rosa Therapeutics Shares Recently? - simplywall.st
Enterprise value to revenue forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Price to earnings forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeutics Inc (GLUE) - GuruFocus
Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeu - GuruFocus
Monte Rosa Therapeutics CEO Markus Warmuth Disposes of Nearly 9,500 Shares at $23.18 Average Price - Kalkine Media
Monte Rosa Therapeutics (GLUE) CEO sells 9,500 shares at about $23 each - Stock Titan
Form 144 MONTE ROSA THERAPEUTICS For: 16 July By Investing.com - Investing.com Nigeria
Monte Rosa: COO Jennifer Champoux sells $101,729 of common stock - Investing.com UK
Price to book forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Monte Rosa Therapeutics (GLUE) reports Q1 loss, misses revenue estimates - MSN
Monte Rosa: COO Jennifer Champoux sells $101,729 of common stock By Investing.com - Investing.com Nigeria
Form 4 Monte Rosa Therapeutics Inc For: 16 July By Investing.com - Investing.com Nigeria
Monte Rosa Therapeutics COO Jennifer Champoux Completes Stock Sales, Option Exercise, and New Grant Under Pre-Arranged Rule 10b5-1 Plan - Kalkine Media
Monte Rosa Therapeutics (GLUE) COO trades 4,351 shares via option exercise - Stock Titan
GLUE (NASDAQ: GLUE) holder to sell 9,500 shares under Rule 144 - Stock Titan
Enterprise value to EBIT forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView
Monte Rosa Therapeutics, Inc. $GLUE is Versant Venture Management LLC's Largest Position - MarketBeat
Monte Rosa COO Jennifer Champoux disposes of 4,351 common shares worth $101,707.28 - Bitget
GLUE (NASDAQ: GLUE) holder plans 4,351-share sale after option exercise - Stock Titan
Trading Systems Reacting to (GLUE) Volatility - Stock Traders Daily
Analysts Are Bullish on These Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Neurocrine (NBIX) - The Globe and Mail
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 8.7%Here's What Happened - MarketBeat
Monte Rosa Therapeutics (GLUE) Recast As A Growth Name As Valuation Questions Build - simplywall.st
T. Rowe Price reports 8.86M-share stake in Monte Rosa Therapeutics (GLUE) - Stock Titan
Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849 - Investing.com
Form 4 Monte Rosa Therapeutics Inc For: 7 July By Investing.com - Investing.com India
Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849 By Investing.com - Investing.com Canada
Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares after option exercise - Stock Titan
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 6.9%Should You Buy? - MarketBeat
AUPH Stock Price and Chart — NASDAQ:AUPH - TradingView
Form 4 Monte Rosa Therapeutics Inc For: 6 July By Investing.com - Investing.com Nigeria
Form 13D/A Monte Rosa Therapeutics For: 6 July By Investing.com - Investing.com South Africa
NEA funds shift 1,000,000 Monte Rosa shares (NASDAQ: GLUE) - Stock Titan
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monte Rosa Therapeutics Inc Stock (GLUE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Champoux Jennifer | Chief Operating Officer |
Jul 15 '26 |
Option Exercise |
3.98 |
4,351 |
17,317 |
66,722 |
| Champoux Jennifer | Chief Operating Officer |
Jul 15 '26 |
Sale |
23.38 |
4,351 |
101,730 |
62,371 |
2.44%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):